The Medicines Company vows to keep fighting US Angiomax patent case
This article was originally published in Scrip
Executive Summary
The Medicines Company has vowed to continue its battle against the US Patent and Trademark Office (PTO) to obtain an extension of the main compound patent (the '404 patent) for its direct thrombin inhibitor Angiomax (bivalirudin) – now that the PTO has again denied a request for an extension. The company is "considering its options, including court challenges".